key: cord-1018514-p2r9ic7v
authors: Burke, Katherine T; McGinnis, Karen Sylvia; Petronic-Rosic, Vesna
title: COVID Toes
date: 2020-12-18
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.12.002
sha: 97c4d38f3433f5e950b2b70a553f9f7b008df112
doc_id: 1018514
cord_uid: p2r9ic7v

More than 40 million people have been infected with the SARS-CoV2 virus since the first infection was reported in December 2019 in Wuhan, China. Multiple reports of cutaneous manifestations of the virus have been described, including a pernio-like eruption. Here we report a case of a healthy 16-year-old girl with a classic presentation of perniosis, now colloquially termed “COVID-toes.” The theories behind the pathogenesis of the condition are reviewed, including possible explanations for why most of the patients affected have minimal systemic symptoms and test negative for COVID-19.

A 16-year-old girl with a history of mild asthma presented in early April 2020 for a new rash on the toes noted three weeks after returning from a family trip to Europe. The rash was intermittently tender and itchy. The patient was otherwise well, and denied preceding or concurrent symptoms of fevers, chills, cough, fatigue, joint pains, or gastrointestinal issues. She lived at home with her parents, both physicians, one working directly with COVID-19 patients, and a sibling. There was no personal or family history of autoimmunity, or hematologic disorders. Photo exam revealed erythematous to purpuric macules and thin papules on the distal aspect of the dorsal toes ( Figure 1 ). Over the course of a few days, the papules became dusky and formed vesicles that later ruptured and began to resolve at the time of her time of presentation ( Figure 2 ). The clinical presentation of tender purpuric papules on the distal toes was most consistent with a diagnosis of perniosis. Four weeks later, only postinflammatory desquamation was present (figure 3). At that time, the patient did not meet clinical criteria to receive COVID-19 testing.

The first cases of infection with the novel coronavirus, SARS-CoV-2, were reported in December 2019 in Wuhan, China. Since then, the virus has spread on a pandemic level, with more than 40 million people infected worldwide. As the number of cases continues to grow, reports of cutaneous manifestations of the virus are coming to light, amongst them a pernio-like eruption. Recognizing cutaneous manifestations of the disease may help provide a diagnostic clue to clinicians and patients to prompt further investigation and intervention.

Case series in Europe and the United States have highlighted the major morphologies of COVID-19 related eruptions. Namely, urticarial, morbilliform, vesicular, papulosquamous, livedo, acro-ischemic, retiform purpura, and pernio-like. Many of these eruptions, such as morbilliform and urticarial, are nonspecific and can be seen in the setting of other viral infections or drug eruptions. A morphology that seems to be unique to coronavirus is the development of pernio-like acral lesions, colloquially named "COVID toes." One of the first reports out of Spain highlighted 6 patients with pernio-like lesions on the distal toes. The majority of the patients either had no coronavirus infection symptoms (cough, fever, body aches, headaches) at the time of rash, or only mild symptoms that either preceded or followed the eruption weeks later. A larger cohort compiled from an international registry of 8 countries reported 318 patients with pernio-like lesions. It was noted that the majority of these patients were generally young and healthy and had mild or no symptoms related to COVID-19 (55% otherwise asymptomatic). In those that exhibited viral symptoms, pernio lesions typically appeared weeks later. This was consistent with an earlier report from Spain where 69% of those with pseudo-chilblains (pernio) developed a rash weeks after initial viral symptoms. Unfortunately, complete viral testing was not available for all patients in any of the mentioned studies, as the mild symptoms associated with the eruption did not meet clinical testing criteria in most countries. Only 7% of patients in the largest international cohort with pernio were confirmed as COVID-19 positive with either PCR or antibody testing.

The lack of positive PCR and serology data in these cohorts raises questions about the pathophysiology and immunologic mechanism behind "COVID-toes" and those affected. Aside from monitoring antibody titers and viral PCRs, recent studies investigated the role of T cells in COVID-19 disease and immunity. Mateus et al. demonstrated T cells in unexposed and asymptomatic individuals that exhibit cross-reactivity between SARS-CoV-2 proteins and proteins in the common cold coronaviruses (HCoVs). They hypothesize that variegated T cell memory to other coronaviruses may help explain the mixed clinical presentations of COVID-19 disease. Braun et al elaborated on this concept and further suggested that young children and adults with more frequent social contacts and exposure to HCoVs may harbor some protective immunity against SARS-Cov-2. Thus, it is possible in those patients, that a robust T cell response to the virus may allow for rapid immunity development before antibodies are produced in large numbers. Additional large-scale studies are needed to validate these hypotheses, but may offer insight into why young patients with "COVID-toes" exhibit negative antibody serology.

In addition to a heterogeneous T cell response, further studies have investigated the variation in interferon (IFN) I levels in patients infected with SARS-CoV-2. COVID-19 is known to trigger the expression of IFN inducible genes that help augment the hosts antiviral behavior. Early IFN-I activation is beneficial to the host, by inhibiting viral replication leading to a more muted or mild clinical course. On the other hand, late activation of IFN-I may be deleterious and exacerbate hypercytokinemia (CRP, IL-6) which leads to poorer clinical outcomes in those infected. The role of interferons, and how they pertain to the development of pernio-like lesions has been described previously in familial chilblain lupus (FCL), an interferonopathy syndrome. The clinical lesions seen in "COVID-toes" are clinically and histologically similar to those seen in FCL. FCL is caused by a mutation in TREX1, and is characterized by excessive, type I IFN production. The type I IFN response plays a vital role in antiviral immunity, but with elevated an inappropriate activation can drive autoimmunity and even induce thrombotic microangiopathy in some patients through direct effects on the microvasculature. The clinical and histologic manifestations of that seen in COVID-toes and TREX1-FCL are similar, and thus the eruption may represent a manifestation of a systemically elevated type I IFN response. Furthermore, it is proposed that the early IFN antiviral response to COVID-19 in young healthy patients may explain the low rates of positive PCR testing and mild clinical courses.

Despite an increased number of cases during the COVID-19 pandemic, there has been little data to support a definite causative role for the SARS-CoV2 virus in the development of perniosis. Colmenero et al examined skin biopsies from 7 pediatric patients presenting with perniosis during the COVID-19 pandemic. None of the patients had a history of rheumatic disease, lupus erythematosus, Raynaud's phenomenon or previous chilblains lesions. Nasopharyngeal and oropharyngeal SARS-CoV2 PCR samples were collected and resulted negative in all cases. Despite negative PCR studies, cytoplasmic granular positivity for SARS-CoV2 spike protein was directly identified in the endothelial cells within capillaries of all specimens examined. The findings were confirmed in one sample with the use of electron microscopy. This study strongly supported a pathogenic role for the virus in the development of chilblains. The histopathologic features identified in their cohort were similar to the features seen in chilblains of other etiologies, which included interface dermatitis with vacuolar degeneration of the basal epidermal layer, and indirect features of vascular damage like red cell extravasation and dermal edema. The authors further state that widespread endothelial infection by the virus plays a role in the pathogenesis of mild and severe forms of the disease. Why some patients present with mild skin limited disease, and others with extensive multi-organ dysfunction is not clear.

Additional case series all together question the direct association between COVID-19 and this pernio eruption. 2 studies by Herman et al. and Roca-Gines et al examined 31 and 20 patients with acral pernio lesions during the time of the pandemic; none of the patients in either study tested positive for SARS-CoV2 PCR, and positive COVID specific antibodies were not detected in a single patient. Some of the patients in each cohort did report a history of Raynaud's or a prior history of chilblains. Both authors propose that lifestyle modifications that were a result of quarantine could explain their findings -such as walking barefoot in unheated homes, inactivity, and time spent in sedentary positions. In the Herman cohort, some patients even reported consumption of recreational drugs, herbal medicines and/or energy drinks. Ultimately, neither group could find any direct causative role that the virus played in the development of perniosis and suggest that the increased rates of pernio that we are seeing are an indirect result of changes in lifestyle behaviors put in place by quarantine measures.

It remains unclear if "COVID-toes" represents a dermatologic marker of an active viral infection, a delayed immune response to the virus during the convalescent phase, or an epiphenomenon not directly caused by COVID-19. There should be ongoing public and physician awareness of the phenomenon of "COVID toes," even if our understanding of the etiology remains unclear. Further research is needed to elucidate the pathogenesis of the condition and pathogenic mechanisms of the SARS-CoV2 virus. 

Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Chilblain-like lesions on feet and hands during the COVID-19 Pandemic

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Type I IFN immunoprofiling in COVID-19 patients

COVID-19) infection-induced chilblains: A case report with histopathologic findings

New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus

When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection

Type I interferon causes thrombotic microangiopathy by a dosedependent toxic effect on the microvasculature

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Evaluation of chilblains as a manifestation of the COVID-19 pandemic

Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic